---
title: "Hong Kong stock movement: CFMEE down 10.88% with no negative news? Increased volatility due to active capital"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296742002.md"
description: "CFMEE fell 10.88%; Tianyue Advanced fell 10.29%, with a transaction amount reaching HKD 148 million; ASMPT fell 3.59%, with a transaction amount reaching HKD 116 million; GCL-Poly fell 1.39%, with a transaction amount reaching HKD 81.43 million; Hantian Tiancheng fell 2.34%, with a market value of HKD 42.7 billion"
datetime: "2026-08-24T05:56:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296742002.md)
  - [en](https://longbridge.com/en/news/296742002.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296742002.md)
generator: "portal-rs"
---

# Hong Kong stock movement: CFMEE down 10.88% with no negative news? Increased volatility due to active capital

**Hong Kong Stock Movement**

CFMEE, down 10.88%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

**Stocks Ranked by Industry Trading Volume**

TianYue Advanced, down 10.29%, with a trading volume of HKD 148 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

ASMPT, down 3.59%, with a trading volume of HKD 116 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

GCL Technology, down 1.39%, with a trading volume of HKD 81.43 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

**Stocks Ranked by Industry Market Capitalization**

Han's Laser, down 2.34%. Based on recent key news:

1.  On August 21, Han's Laser was included in the Hang Seng Composite Index, expected to take effect on September 7. This move may lead to its inclusion in the Hong Kong Stock Connect, increasing investor attention. However, the stock price has fallen in the short term, possibly due to the market's wait-and-see attitude regarding its performance post-inclusion. Source: Zhitong Finance

2.  On August 21, Han's Laser announced a net profit expectation of 44 million to 54 million yuan for the first half of 2026, a significant improvement compared to a net loss of 2 million yuan in the same period of 2025. Despite the positive performance expectations, the market reaction was below expectations, and the stock price still declined. Source: Zhitong Finance. The Hong Kong stock market has been volatile recently, and investors should exercise caution

### Related Stocks

- [09630.HK](https://longbridge.com/en/quote/09630.HK.md)
- [02631.HK](https://longbridge.com/en/quote/02631.HK.md)
- [00522.HK](https://longbridge.com/en/quote/00522.HK.md)
- [03800.HK](https://longbridge.com/en/quote/03800.HK.md)
- [02726.HK](https://longbridge.com/en/quote/02726.HK.md)

## Related News & Research

- [Circuit Fabology Microelectronics Equipment announces extraordinary shareholder meeting](https://longbridge.com/en/news/297048205.md)
- [ANALYSIS-Investors heartened by Warsh inflation talk, still uncertain about Fed action](https://longbridge.com/en/news/297468486.md)
- [MicroPort says pooled AMI trial analysis supports aspirin withdrawal after 1-month DAPT post-PCI, cuts major bleeding 52%](https://longbridge.com/en/news/298004193.md)
- [Why Philippine chain Jollibee chose Hong Kong over New York to list spin-off](https://longbridge.com/en/news/297760396.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**